Larotrectinib in adult patients with TRK fusion cancer: an expanded data set


The highly selective TRK inhibitor Larotrectinib ( Vitrakvi ) is approved for the treatment of adult and pediatric cancers that harbor NTRK gene fusions; it achieves a 79% overall response rate ( ORR ) in this population ( Hong et al., Lancet Oncol 2020 ).
The activity of Larotrectinib in adults alone was further characterized in this update with a larger series of patients and more mature durability data.

Adults ( aged 18 years or older ) with TRK fusion cancer treated in three Larotrectinib clinical trials ( NCT02122913, NCT02576431, and NCT02637687 ) were analyzed.
Larotrectinib was administered 100 mg BID until disease progression, withdrawal, or unacceptable toxicity.
ORR was investigator-assessed ( RECIST v1.1 ).
Compared to previously presented data on 74 patients, this expanded data set has included an additional 42 patients ( data cutoff: July 15, 2019 ).

116 adults ( median age: 56 years, range 19–84 years; 53% female ) with TRK fusion cancer were treated.

Tumor types included thyroid cancer ( 22% ), salivary gland cancer ( 19% ), soft tissue sarcoma ( 16% ), lung cancer ( 12% ), colon cancer ( 7% ), melanoma ( 5% ), breast cancer ( 5% ), GIST ( 3% ), and 9 other types ( 2% or less each ).

NTRK fusions involved NTRK1 ( 43% ), NTRK2 ( 3% ), and NTRK3 ( 54% ).

78% of patients had received prior systemic therapy ( with 68% of those receiving 2 or more prior therapies ).

The ORR was 71% ( 95% CI 62–79 ): 10% complete response [ CR ], 60% partial response [ PR ] ( 2% pending confirmation ), 16% stable disease, 9% progressive disease, 3% not determined.

In patients with brain metastases, the ORR was 71% ( 95% CI 42–92; 10 of 14 patients, all partial responses ).

Median duration of response for the overall data set ( n = 116 ) was 35.2 months ( 95% CI 21.6–not estimable [ NE ] ).

Median progression-free survival was 25.8 months ( 95% CI 15.2–NE ). Median overall survival was not reached ( range 0.5+ to 51.6+ months ) at a median follow-up of 15.8 months.

Duration of treatment ranged from 0.10 to 51.6+ months.

12% of patients had dose reductions. One patient ( 1% ) discontinued due to a Larotrectinib-related adverse event.
Adverse effects were mostly grade 1–2; no new unexpected adverse effects were reported.

In conclusion, in an expanded data set of adults with TRK fusion cancer, Larotrectinib demonstrated robust and durable tumor-agnostic efficacy and favorable safety, supporting NTRK gene fusion testing in patients with solid tumors of any type. ( Xagena )

Source: American Society of Clinical Oncology ( ASCO ) Virtual Meeting, 2020

XagenaMedicine_2020



Indietro

Altri articoli

Data from the five-year analysis featuring extended follow-up from the phase III COMBI-AD study have confirmed that 12 months of...


There has been an only indirect comparison between Pembrolizumab ( Keytruda ) and Pembrolizumab plus chemotherapy in patients with non-small...


The aim of neo-adjuvant therapy in locally advanced or oligometastatic melanoma is to facilitate radical resection, improve outcomes and undertake...


The ALEX study has demonstrated significantly improved progression-free survival ( PFS ) with Alectinib ( Alecensa ) versus Crizotinib (...


In the absence of effective vaccines and with limited therapeutic options, convalescent plasma is being collected across the globe for...


The mRNA-1273 vaccine for SARS-CoV-2 is tolerable and immunogenic in older adults. Data on prolonged immunogenicity and effectiveness in preventing severe...


The European Commission ( EC ) has granted conditional marketing authorization to Ayvakyt ( Avapritinib ) as a monotherapy for...


The U.S. Food and Drug Administration ( FDA ) has approved Gallium 68 PSMA-11 ( Ga 68 PSMA-11 ), the...


The FDA ( U.S. Food and Drug Administration ) has approved Ayvakit ( Avapritinib ) for the treatment of adults...


The European Commission ( EC ) has granted marketing authorisation for the expanded use of Erleada ( Apalutamide ) to...